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BACKGROUND Recent DWI-controlled CARENET study indicated
periprocedural cerebral embolization paramount reduction (>50%
incidence, >10-fold volume) using a novel MicroNet-covered embolic
prevention stent system as compared to conventional CAS, plus no
cerebral embolization throughout the healing period.
METHODS PARADIGM [Prospective evaluation of All-comer peRcuta-
neous cArotiD revascularization In symptomatic and increased-risk
asymptomatic carotid artery stenosis using CGuard Micronet-
covered embolic prevention stent system] evaluated feasibility and
outcome of routine anti-embolic stent use in unselected pts referred
for carotid revascularization. Consecutive referrals were tracked (all-
comer six-month sample, industry-independent academic study).
Decisions on revascularization (yes/no) and its method were made
(CGuard fully available) by a multidisciplinary NeuroVascular Team
(neurologist, interventional angiologist, vascular surgeon, cardiolo-
gist); asymptomatic pts required 1 evidenced lesion-level increased-
risk criterion. Outcome analyses were performed by independent
CoreLab.
RESULTS Of 97 referrals in 6 months, 24 were deferred (in most -
lesion increased risk criteria unmet). Carotid revascularization was
thus performed in 73 pts (CAS-only in 67, bilateral in 3, CASþCEA in 1,
CEA in 5), yielding 71 CAS in 68 pts (697y, 66% male, 53% symp-
tomatic, 9% emergent CAS in evolving stroke). CGuard was used in
100% of CAS (ie, zero cross-over to other stent/s), proximal/distal EPD
use was 35/65%. CAS lesions were thrombus-containing (15%), near-
occlusive/string (21%), highly-calciﬁc (23%) (CoreLab). ICA RVD was
4.990.96mm, lesion length was 19.95.8mm. Diameter stenosis was
reduced from 829 to only 74% (p<0.001); consistent with endo-
vascular reconstruction of the carotid bifurcation with fully main-
tained ECA patency. Implanted stents were 29.660.30 and
39.730.34 for nominal 30mm (74.6%) and 40mm length, indicating
lack of any foreshortening/elongation. PSV/EDV were 3.81.3/1.30.7
at B/L vs. 0.700.28/0.170.07 m/s in-stent (p<0.001). In this
increased-risk sample, CGuard technical success was 100% and pro-
cedural success was 100%. Death/any stroke/MI rate was 0% at 48h
and 0% at 30 days (CEC, independent neurologist and non-interven-
tional cardiologist evaluation).
CONCLUSIONS 1. Over 90% of unselected contemporary carotid ar-
tery stenosis patients indicated to require revascularization (Neuro-
Vascular Team), including >50% symptomatic presentations, can be
treated endovascularly using the MicroNet-covered embolic preven-
tion stent CGuard; this is effective in achieving full endovascular
reconstruction of ICA across all-comer lesion subsets in absence of
periprocedural and 30-day complications. 2. The PARADIGM study
provides accumulating evidence for a novel carotid revascularization
decision-making model using the MicroNet-covered embolic preven-
tion stent system as a signiﬁcant technological advancement trans-
lating into maximized patient safety in routine clinical practice.
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BACKGROUND Carotid stenting (CAS) is typically performed using
embolic protection devices (EPDs) as a means to reduce procedure-
related stroke. In this study, we compared procedural complications,
morbidity and mortality across two different strategies: distal (D-EPD)
and proximal (P-EPD) protection.
METHODS MEDLINE, EMBASE and the Cochrane Central Register of
Controlled Trials were queried from January 1998 through May 2015.
Only studies comparing (D-EPD) and (P-EPD) were included. Two in-
dependent reviewers selected and appraised studies and extracted
data in duplicate. Random-effects meta-analysis was used to pool
outcomes across studies. Heterogeneity of treatment effect among
studies was assessed using the I2 statistics. Publication bias was
assessed using inspection of funnel plots. The primary endpoints
included mortality and stroke. Secondary endpoints included new
cerebral lesions on diffusion-weighted magnetic resonance imaging
(DW-MRI), contralateral lesions on DW-MRI, transient ischemic at-
tacks (TIA) and internal carotid artery spasm.
RESULTS A total of 12281 patients were included from eighteen
studies (13 prospective and 5 retrospective) comparing (D-EPD) and
(P-EPD) in the setting of CAS. Mean age was 69 years and 64% of
patients were male. No evidence of publication bias was detected.
There was no signiﬁcant difference between the two modalities in the
risk of stroke (risk difference [RD] 0.0, 95% conﬁdence interval [CI]
-0.01 to 0.01) or mortality (RD 0.0, 95% CI -0.01 to 0.01) nor was there
any difference in the incidence of new cerebral lesions on DW-MRI,
contralateral DW-MRI lesions, TIA or ICA spasm.
Study/Year Study Type
Study
Primary
Endpoint(s)
Distal Filter Protection Proximal Balloon Occlusion
N TIA Stroke
New
Cerebral
Lesions
Contralateral
Lesions on
DW MRI Mortality
ICA
Spasm N TIA Stroke
New
Cerebral
Lesions
Contralateral
Lesions on
DW MRI Mortality
ICA
Spasm
Akkaya 2014 Prospective
(Randomized)
New cerebral
lesions on
DW-MRI
46 0 3 30 3 0 N/A 48 0 2 19 2 0 N/A
Bijuklic 2012 Prospective
(Randomized)
New cerebral
lesions on
DW-MRI
31 0 1 27 9 0 N/A 31 0 0 14 2 0 N/A
Cano 2013 Prospective
(Randomized)
New cerebral
lesions on
DW-MRI
30 0 1 19 11 0 N/A 30 0 0 20 8 0 N/A
Castro-
Afonso
2013
Prospective
(Randomized)
New cerebral
lesions on
DW-MRI
19 1 0 3 3 0 N/A 21 1 0 10 3 0 N/A
El-Koussy
2007
Prospective
(Randomized)
New cerebral
lesions on
DW-MRI
19 0 2 6 1 1 N/A 25 0 2 7 5 0 N/A
Grego 2002 Prospective
(Randomized)
Stroke/TIA/
Mortality
13 0 0 N/A N/A 0 3 13 0 0 N/A N/A 0 3
Leal 2012 Prospective
(Randomized)
New cerebral
lesions on
DW-MRI
33 0 0 13 2 0 N/A 31 0 0 4 0 0 N/A
Montorsi
2011
Prospective
(Randomized)
New cerebral
lesions on
DW-MRI
21 0 1 9 N/A 0 N/A 14 0 0 2 N/A 1 N/A
Schmidt
2004
Prospective
(Randomized)
Stroke/TIA 21 1 0 N/A N/A 0 N/A 21 0 0 N/A N/A 0 N/A
Taha 2009 Prospective
(Randomized)
New cerebral
lesions on
DW-MRI
4 N/A N/A 2 1 0 N/A 34 N/A N/A 26 11 0 N/A
Tatli 2013 Prospective
(Randomized)
Stroke/TIA/
Mortality
40 1 0 N/A N/A 0 9 48 0 0 N/A N/A 0 1
Flach 2007 Prospective
(Observational)
New cerebral
lesions on
DW-MRI
23 0 0 8 0 0 N/A 10 0 0 4 0 0 N/A
Brewster
2011
Retrospective
(Observational)
Stroke/MI/
Mortality
216 N/A 7 N/A N/A 3 N/A 53 N/A 0 N/A N/A 0 N/A
Fernandez
2014
Restrospective
(Observational)
Stroke/MI/
Mortality
208 0 9 N/A N/A 4 N/A 79 0 3 N/A N/A 1 N/A
Giri 2015 Restrospective
(Observational)
Stroke/
Mortality
2032 N/A 33 N/A N/A 9 N/A 508 N/A 8 N/A N/A 1 N/A
Mokin 2014 Retrospective
(Observational)
Stroke/TIA/
Mortality
70 1 1 N/A N/A 0 N/A 70 1 1 N/A N/A 0 N/A
Pieniazek
2008
Prospective
(Randomized)
Stroke/
Mortality
396 N/A N/A N/A N/A N/A 13 139 N/A N/A N/A N/A N/A 0
Powel 2006 Retrospective
(Observational)
Stroke/TIA/
Mortality
42 0 2 N/A N/A N/A 12 99 1 3 N/A N/A N/A 2
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appear to provide similar levels of protection from peri-procedural
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